Papers

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

M R Law, N J Wald, A R Rudnicka

Abstract

Objectives To determine by how much statins reduce serum concentrations of low density lipoprotein (LDL) cholesterol and incidence of ischaemic heart disease (IHD) events and stroke, according to drug, dose, and duration of treatment.

Design Three meta-analyses: 164 short term randomised placebo controlled trials of six statins and LDL cholesterol reduction; 58 randomised trials of cholesterol lowering by any means and IHD events; and nine cohort studies and the same 58 trials on stroke.

Main outcome measures Reductions in LDL cholesterol according to statin and dose; reduction in IHD events and stroke for a specified reduction in LDL cholesterol.

Results Reductions in LDL cholesterol (in the 164 trials) were 2.8 mmol/l (60%) with rosuvastatin 80 mg/day, 2.6 mmol/l (55%) with atorvastatin 80 mg/day, 1.8 mmol/l (40%) with atorvastatin 10 mg/day, lovastatin 40 mg/day, simvastatin 40 mg/day, or rosuvastatin 5 mg/day, all from pretreatment serum concentrations of 4.8 mmol/l. Pravastatin and fluvastatin achieved smaller reductions. In the 58 trials, for an LDL cholesterol reduction of 1.0 mmol/l the risk of IHD events was reduced by 11% in the first year of treatment, 24% in the second year, 33% in years three to five, and by 36% thereafter (P < 0.001 for trend). IHD events were reduced by 20%, 31%, and 51% in trials grouped by LDL cholesterol reduction (means 0.5 mmol/l, 1.0 mmol/l, and 1.6 mmol/l) after results from first two years of treatment were excluded (P < 0.001 for trend). After several years a reduction of 1.8 mmol/l would reduce IHD events by an estimated 61%. Results from the same 58 trials, corroborated by results from the nine cohort studies, show that lowering LDL cholesterol decreases all stroke by 10% for a 1 mmol/l reduction and 17% for a 1.8 mmol/l reduction. Estimates allow for the fact that trials tended to recruit people with vascular disease, among whom the effect of LDL cholesterol reduction on stroke is greater because of their higher risk of thromboembolic stroke (rather than haemorrhagic stroke) compared with people in the general population.

Conclusions Statins can lower LDL cholesterol concentration by an average of 1.8 mmol/l which reduces the risk of IHD events by about 60% and stroke by 17%.

Introduction

Statins are highly effective in lowering serum cholesterol concentrations and preventing ischaemic heart disease (IHD). Three issues remain. We do not know by how much different statins at different doses reduce low density lipoprotein (LDL) cholesterol concentrations. There are indications from previous studies but there has been no systematic review of placebo controlled trials. Secondly, the full effect of statins in preventing IHD events has not been specified. The 30% reduction shown in meta-analyses of major randomised trials underestimated the full effect because IHD events in the first two years (before the full effect of reducing serum LDL cholesterol concentrations is achieved) were not censored, many trials used less effective statins, and trials were affected by non-adherence to the allocated regimen (those on statins not taking them and those on placebo taking statins). Thirdly, there is a paradox in that meta-analyses of randomised trials showed that statins reduced the incidence of strokes by about 30% but cohort studies showed no association between serum cholesterol concentrations and stroke.

Methods

We carried out three analyses. The first was a meta-analysis of 164 short term (typically a few weeks) randomised placebo controlled trials of six statins (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, and rosuvastatin (recently marketed), used in fixed dose). The meta-analysis examined the efficacy of reducing total and LDL cholesterol by dose and pretreatment serum cholesterol concentrations. The second meta-analysis was of 58 randomised trials (including eight of the above 164 trials) of reducing serum cholesterol concentration by any means and IHD events to estimate the reduction in risk by LDL cholesterol reduction and duration of treatment. This updates our 1994 analyses. In the third analysis we examined data from nine cohort studies and the 58
randomised trials to determine the effect of a decrease in LDL cholesterol concentration on thromboembolic, haemorrhagic, fatal, and non-fatal stroke.

164 short term trials of statins and LDL cholesterol reduction

We searched Medline, Cochrane Collaboration, and Web of Science databases (see [www.smd.cam.ac.uk/ wolfson/bpchol for details and webextra for full list of references]). We included all double blind trials, irrespective of participants' age or disease. Participants in most trials were healthy with above average lipid concentrations. In some trials they had high blood pressure, diabetes, or IHD. We excluded trials that had no placebo group, lasted less than two weeks, used variable doses (titrating), or used cholesterol lowering drugs in combination, and trials in which the order of treatment and placebo periods in crossover trials was not randomised or patients had chronic renal failure or organ transplantation.

We defined drug efficacy as the reduction in LDL cholesterol concentration for a given dose, expressed as the change in the treated group minus that in the placebo group (in crossover trials end treatment minus end placebo concentration). Methods for calculating standard errors and the statistical analyses are described in the accompanying paper.

58 randomised trials of serum cholesterol reduction (by any means) and IHD events

We expanded the literature search to include methods of reduction of serum cholesterol concentrations other than statins; 33 more recent trials and 25 reported in 1994 met inclusion criteria. We excluded trials in which risk factors other than lipids were changed, LDL cholesterol reduction was <0.2 mmol/l, fewer than five IHD events were recorded, or there was no untreated control group. We calculated the absolute change in serum LDL cholesterol concentration in the treatment group minus that in the placebo group. In 17 of the 25 earlier trials LDL cholesterol was not measured so we used total serum cholesterol concentration. We defined IHD events as IHD death or non-fatal myocardial infarction, ignoring subsequent events in an individual and excluding "silent" infarcts. In each trial we determined the numbers of IHD events and the changes in LDL cholesterol (adjusted for placebo) separately for years one, two, three to five, and six or more after trial entry. We recorded disease events and the average reduction in LDL cholesterol concentration in all randomised participants regardless of compliance (assuming LDL concentration reverted to baseline when participants left the trial).

We combined the odds ratios (treated/placebo) of disease events, stratified according to duration of scheduled treatment, to yield summary estimates using a random effects model. After the effects of reduction in LDL cholesterol and duration of treatment were taken into account there was no significant residual heterogeneity. We standardised each trial result to an LDL cholesterol reduction of 1.0 mmol/l by raising the observed odds ratio to the power of (1.0 divided by the observed LDL cholesterol reduction).

Nine cohort studies and 58 randomised trials of serum cholesterol and stroke

We identified nine cohort studies of serum cholesterol concentration and stroke that distinguished thromboembolic and haemorrhagic strokes using computed tomography or postmortem findings. We used Medline (1980 to October 2002; key and text words blood cholesterol and [cerebral haemorrhage or intracranial haemorrhages or subarachnoid haemorrhage or cerebral infarction]). We determined the difference in incidence for a difference in LDL cholesterol of 1.0 mmol/l adjusted for regression and surrogate dilution bias. Data on stroke from the 58 randomised trials were combined by using a random effects model. There was no significant heterogeneity.
Table 2 Absolute reductions* (mmol/l) with 95% confidence intervals and percentage reductions† in serum LDL cholesterol concentration according to statin and daily dose (summary estimates from 164 randomised placebo controlled trials)

<table>
<thead>
<tr>
<th>Statin</th>
<th>Daily dose (mg)</th>
<th>5</th>
<th>10</th>
<th>20</th>
<th>40</th>
<th>80</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atorvastatin</td>
<td>1.51 (1.28 to 1.74), 31%</td>
<td>1.79 (1.62 to 1.97), 37%</td>
<td>2.07 (1.90 to 2.25), 43%</td>
<td>2.36 (2.12 to 2.59), 49%</td>
<td>2.64 (2.31 to 2.96), 55%</td>
<td></td>
</tr>
<tr>
<td>Fluvastatin</td>
<td>0.46 (0.18 to 0.75), 10%</td>
<td>0.74 (0.55 to 0.93), 15%</td>
<td>0.92 (0.80 to 1.13), 21%</td>
<td>1.30 (1.19 to 1.41), 27%</td>
<td>1.54 (1.40 to 1.76), 33%</td>
<td></td>
</tr>
<tr>
<td>Lovastatin</td>
<td>—</td>
<td>1.02 (0.71 to 1.34), 21%</td>
<td>1.40 (1.21 to 1.59), 29%</td>
<td>1.77 (1.60 to 1.94), 37%</td>
<td>2.15 (1.86 to 2.43), 45%</td>
<td></td>
</tr>
<tr>
<td>Pravastatin</td>
<td>0.73 (0.54 to 0.92), 15%</td>
<td>0.95 (0.63 to 1.07), 20%</td>
<td>1.11 (1.10 to 1.23), 24%</td>
<td>1.36 (1.31 to 1.46), 29%</td>
<td>1.60 (1.46 to 1.74), 33%</td>
<td></td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>1.84 (1.74 to 1.94), 38%</td>
<td>2.08 (1.86 to 2.18), 43%</td>
<td>2.32 (2.20 to 2.44), 48%</td>
<td>2.56 (2.42 to 2.70), 53%</td>
<td>2.80 (2.63 to 2.97), 58%</td>
<td></td>
</tr>
<tr>
<td>Simvastatin</td>
<td>1.09 (0.93 to 1.22), 23%</td>
<td>1.31 (1.12 to 1.40), 27%</td>
<td>1.54 (1.46 to 1.63), 32%</td>
<td>1.79 (1.66 to 1.90), 37%</td>
<td>2.01 (1.83 to 2.19), 42%</td>
<td></td>
</tr>
</tbody>
</table>

*Absolute reductions are standardised to usual serum LDL cholesterol concentration of 4.8 mmol/l before treatment (mean concentration in trials).
†Percentage reductions are independent of pretreatment LDL cholesterol concentration; 95% confidence intervals on percentage reductions can be derived by dividing those on absolute reductions by 4.8.

Table 3 Reduction in risk (95% confidence intervals) of ischaemic heart disease events* for 1.0 mmol/l decrease in serum LDL cholesterol concentration, according to number of years in trial (58 trials)

<table>
<thead>
<tr>
<th>Year in trial</th>
<th>% Reduction in risk</th>
<th>1st 11 (4 to 18)</th>
<th>2nd 24 (17 to 30)</th>
<th>3rd-5th 33 (28 to 37)</th>
<th>6th and subsequent 36 (28 to 45)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st 11</td>
<td>10 (4 to 18)</td>
<td>11 (11 to 18)</td>
<td>10 (4 to 18)</td>
<td>11 (11 to 18)</td>
<td>10 (4 to 18)</td>
</tr>
<tr>
<td>2nd 24</td>
<td>24 (17 to 30)</td>
<td>24 (17 to 30)</td>
<td>24 (17 to 30)</td>
<td>24 (17 to 30)</td>
<td>24 (17 to 30)</td>
</tr>
<tr>
<td>3rd-5th 33</td>
<td>33 (28 to 37)</td>
<td>33 (28 to 37)</td>
<td>33 (28 to 37)</td>
<td>33 (28 to 37)</td>
<td>33 (28 to 37)</td>
</tr>
<tr>
<td>6th and sub</td>
<td>36 (28 to 45)</td>
<td>36 (28 to 45)</td>
<td>36 (28 to 45)</td>
<td>36 (28 to 45)</td>
<td>36 (28 to 45)</td>
</tr>
</tbody>
</table>

*IHD death and non-fatal myocardial infarction.

Results

164 short term trials of statins and LDL cholesterol reduction

Table 1 shows details of the 164 trials. There were about 24 000 treated and 14 000 placebo participants (individual trial data on can be found on www.sdcm.qmul.ac.uk/wolfson/bpchol).

Figure 1 shows the dose-response relations for the five statins across the doses tested (2.5-80 mg/day). The straight lines fit the data well. With simvastatin the linear trend is unconvincing above 20 mg/day, but one study (excluded from our meta-analysis because it had no placebo group) confirmed greater efficacy at higher doses.5

Table 2 shows the estimated reductions in LDL cholesterol, according to statin and dose, calculated from the straight lines and standardised to the average pretreatment LDL cholesterol concentration in these trials (4.8 mmol/l; about the average in people having an IHD event). Rosuvastatin 5 mg/day, atorvastatin 10 mg/day, and lovastatin or simvastatin 40 mg/day reduced LDL cholesterol concentrations by about 35% (1.8 mmol/l), but fluvastatin and pravastatin produced smaller reductions even at the highest doses tested (80 mg/day). Rosuvastatin 10 mg/day, atorvastatin 20 mg/day, and lovastatin or simvastatin 80 mg/day reduced concentrations by about 45% (2.1 mmol/l) and rosuvastatin 80 mg/day by about 60% (2.39 mmol/l).

Statins significantly lowered LDL cholesterol from all pretreatment concentrations. The absolute reductions (in mmol/l) were greater in those with higher pretreatment concentrations. The percentage reductions were independent of pretreatment concentrations and therefore more generalisable, but we adopted absolute reductions because the relations with disease events were quantified by using absolute cholesterol reductions. If the pretreatment concentration was 1 mmol/l higher (5.8 mmol/l), LDL cholesterol reduction was on average 0.28 mmol/l greater. No effect of age was apparent, but there was little variation in average age across trials.

In these 164 trials atorvastatin and rosuvastatin were taken in the morning but the other statins in the evening. In four randomised comparisons in three trials27,31,115,113 the average reduction was 0.20 mmol/l smaller with morning dose than with evening dose (95% confidence interval 0.05 mmol/l to 0.44 mmol/l smaller). Doubling the dose has a similar effect (about 0.20 mmol/l) and so would counter this. The greater effect of evening dose arises because of short biological half life (peak cholesterol synthesis occurs at night).

Atorvastatin and rosuvastatin have longer half lives half life (peak cholesterol synthesis occurs at night). Atorvastatin and rosuvastatin have longer half lives and avoid this problem; lipid changes with atorvastatin were similar with morning and evening dose.37

The reductions in total and LDL cholesterol concentrations were highly correlated across trials (r=0.83). On average, a reduction in LDL cholesterol of 1.0 mmol/l was associated with a total cholesterol reduction of 1.20 mmol/l (1.10 mmol/l to 1.31 mmol/l). If only total serum cholesterol reduction were measured, we would expect the absolute reduction in LDL cholesterol to be 17% less (1.0 minus 1.0/1.20). The reduction in VLDL cholesterol was on average 10% of the reduction in LDL cholesterol shown in table 2. Statins increased HDL cholesterol by 0.07 mmol/l (0.06 mmol/l to 0.08 mmol/l) on average, with no detectable effect of dose.

58 trials of serum cholesterol reduction and IHD events

These 58 trials included 76 359 participants allocated treatment and 71 962 controls, with 5440 and 7102 IHD events respectively: 52% of participants had known vascular disease on entry. See webextra tables A and B for details.

Table 3 shows the reduction in IHD events by duration of treatment; each trial result is standardised to a reduction in LDL cholesterol of 1.0 mmol/l (about the average reduction in the trials). In the first year the reduction was 11%, in the second 24%, and in the first and second years combined 13%. Data from 12 trials with event numbers published for the first two years but not the first and second years separately yielded a similar result. The reduction in the third, fourth, and fifth years combined was 33%, and the sixth and subsequent years was 36%. After standardisation for reduction in LDL cholesterol and duration of treatment, risk reduction was similar for fatal and non-fatal IHD events, for different methods of reducing serum cholesterol (fibrates, resins, niacin, statins, or dietary change), and in participants with and without known IHD on entry (showing that the proportional risk reduction model applies regardless of initial risk).
Table 4 shows the combined effect of duration of treatment and reduction in LDL cholesterol directly. The trials tend to cluster into three groups, with mean reductions of LDL cholesterol of 0.5 mmol/l (n = 21), 1.0 mmol/l (n = 24), and 1.6 mmol/l (n = 5). Across these groups, the greater the reduction in LDL cholesterol the greater the reduction in IHD events. With a reduction in LDL cholesterol of around 1.6 mmol/l the reduction in IHD events after two or more years’ treatment was 51%.

Serum cholesterol and stroke

Nine cohort studies

Figure 2 shows the relative risk of thromboembolic and haemorrhagic strokes (subarachnoid (SAH) and intracerebral haemorrhage (ICH)) for a 1.0 mmol/l decrease in LDL cholesterol concentration from cohort studies that distinguished the two. Overall there was a 15% (6% to 21%) decrease in thromboembolic stroke (P < 0.001) and a 19% (10% to 29%) increase in haemorrhagic stroke (P < 0.001). The similar relative risk estimates for subarachnoid (1.16) and intracerebral haemorrhage (1.22) justify combining them as “haemorrhagic stroke.”

The opposing effects of thromboembolic and haemorrhagic stroke explain the absence of an association between serum cholesterol and stroke in a meta-analysis of 45 cohort studies.11 Death from the two types of stroke cancelled each other because the 45 cohort studies generally recorded only fatal stroke and at age 60 (the average in the studies) about half of fatal strokes are thromboembolic and half are haemorrhagic.18-210-214 These data also show that at age 60, 76% of non-fatal strokes are thromboembolic and 24% haemorrhagic, and 71% of all strokes are thromboembolic and 29% haemorrhagic18 (the difference from fatal stroke explained by the greater chance of dying from a haemorrhagic stroke). Application of the change in risk for type of stroke to these percentages yields an expected decrease in non-fatal stroke (per 1 mmol/l reduction in LDL cholesterol) of 7% (a 15% decrease in 76% plus a 19% increase in 24%). Similarly the expected decrease for all stroke is 6%.

58 trials of cholesterol reduction by any means and disease events

Fifty six of the 58 trials reported on deaths from stroke (though in 21 trials none occurred) and 40 reported on
non-fatal strokes (in 10 none occurred) (see webextra tables A and B for details).

Table 5 shows the main results on stroke from randomised trials and the above expected results from the nine cohort studies, standardised to an LDL cholesterol reduction of 1.0 mmol/l. Stroke risk in all the trials was reduced by 20% on average (P < 0.001), but this varied. In people without known vascular disease the reduction was the same (-0.0%) as that expected from cohort studies, but in people with known vascular disease it was higher (-22% - 0% P < 0.001). This difference probably arises because thromboembolic stroke is common in people with vascular disease so more of their strokes will be thromboembolic. Results from the six randomised trials in people with known vascular disease that distinguished the two types of stroke confirmed this: 91% of the strokes in the placebo groups were thromboembolic (78% - 73%) and 9% haemorrhagic, whereas in the stroke registry studies in people the same age without known vascular disease the proportion of stroke was the same (0%). As expected from cohort studies, but in people with known vascular disease it was higher (-22% - 0% P < 0.001). This difference probably arises because thromboembolic stroke is common in people with vascular disease so more of their strokes will be thromboembolic. Results from the six randomised trials in people with known vascular disease that distinguished the two types of stroke confirmed this: 91% of the strokes in the placebo groups were thromboembolic (78% - 73%) and 9% haemorrhagic, whereas in the stroke registry studies in people the same age without known vascular disease the proportion of stroke was the same (0%).

The 20% reduction in stroke for a 1.0 mmol/l reduction in LDL cholesterol concentration prevents thromboembolic but not haemorrhagic strokes, accounting for the greater than expected effect of treatment in people with vascular disease. This also explains the greater than expected reduction in non-fatal stroke in shown table 5 (-25% - 7% P < 0.001) as most non-fatal strokes are thromboembolic. The absence of a material reduction in fatal stroke in the trials corroborates the cohort study observations.

The 20% reduction in stroke for a 1.0 mmol/l reduction in LDL cholesterol concentration is therefore specific to these trial populations in which 80% of all strokes were in people with known vascular disease. In the general population, stroke registry data indicate that about 25% of first strokes are in people with known vascular disease. Therefore a reduction of 1.0 mmol/l in LDL cholesterol would reduce stroke in the general population by 10% (25% of the 22% reduction in people with known vascular disease and 75% of the 6% reduction in people without known vascular disease, from table 5).

Three large trials showed little or no reduction in incidence of stroke until the second year, as for HbA1c increase. The reductions in all stroke, thromboembolic stroke, and non-fatal stroke shown in table 5 would, therefore, be greater if events occurring in the first 1-2 years were excluded.

**Adverse effects**

Forty eight of the 164 trials of statins and LDL cholesterol reported the number of participants with one or more symptoms possibly caused by the drug (1063/14197 allocated to statins and 925/10508 allocated to placebo). Meta-analysis of these data showed no excess risk in people allocated to statins. On average 1% fewer treated patients than placebo patients reported symptoms (95% confidence interval 3% fewer to 1% more in treated patients). The prevalence of each of 12 specific symptoms, including muscle pain and various gastrointestinal symptoms, was similar in treated and placebo patients, even for the highest daily dose tested (80 mg for all six statins). The upper confidence limits excluded the possibility that statins caused any symptom in more than 2% of treated patients.

The only known serious adverse effects of statins are rhabdomyolysis and liver failure from hepatitis. The absolute risks are low. In the trials of statins and adverse events, with about 35 000 people and 158 000 person years of observation in both treated and placebo groups (see webextra table A), rhabdomyolysis was diagnosed (variable criteria) in eight treated and five placebo patients, none with serious illness or death. Raised serum creatine kinase activity (≥ 10 times the upper limit of normal) was reported in 35 treated patients (0.17%) and 43 placebo patients (0.13%); muscle symptoms were present in 13 and 4 respectively. From the first marketing of statins in 1987 to May 2001 the Food and Drug Administration recorded 42 deaths from rhabdomyolysis attributable to statins (other than cerivastatin, which was not used in these trials) in the United States, a rate of one per 10 million prescriptions dispensed or (as a prescription is typically for one month's supply) about one per million person years of use. There were no cases of liver failure in the trials. Raised alanine aminotransferase activity (≥ 3 times the upper limit of normal, used to recognise hepatitis) was reported in 449 treated (1.3%) and 383 placebo patients (1.1%) (see webextra table A). From 1987 to May 2000 the Food and Drug Administration recorded 30 cases of liver failure attributable to statins, again about one per million person years of use.
Concern over hazards from serum cholesterol reduction was resolved by earlier studies. Data from the 58 randomised trials of cholesterol reduction and disease events confirm this. The odds ratios (treated/placebo) for a 1.0 mmol/l decrease in serum cholesterol were 0.87 (0.73 to 1.03; 675 deaths) for circulatory diseases other than IHD and stroke, 1.06 (0.96 to 1.16; 2293 deaths) for cancer, 0.94 (0.72 to 1.23; 324 deaths) for injuries and suicide, and 0.88 (0.78 to 1.01; 1303 deaths) for diseases other than circulatory diseases and cancer.

Discussion
Randomised trials show directly that a reduction in LDL cholesterol of 1.6 mmol/l halves the risk of IHD events after two years and that this reduction can be achieved with low doses of some statins (for example, simvastatin 20 mg/day, table 2). Certain statins achieve larger reductions (for example, 2.6 mmol/l with atorvastatin 80 mg/day and 2.8 mmol/l with rosuvastatin 80 mg/day), which would lead to greater reductions in IHD events, but the corresponding risk reduction cannot be quantified directly from randomised trials as no trial achieved so large a reduction. This can be determined from cohort studies of cholesterol and IHD if cohort studies accurately predicted trial results. Table 6 shows the reduction in IHD events in the trials after the exclusion of data from the first two years and those expected from cohort study results. Observed trial and expected cohort study results are close, showing that cohort study data can be used to predict risk reduction from lowering LDL cholesterol. The similarity between trial and cohort study data, and the similar reductions in risk (given cholesterol reduction) with different methods of lowering cholesterol, indicate that the reduction in risk is directly attributable to cholesterol reduction; there is no need to invoke other actions of drugs.

Table 7 shows the reductions in IHD events at different ages predicted from the cohort studies. At age 60 years a 2.2 mmol/l reduction in serum LDL cholesterol concentration (attainable by using atorvastatin 40 mg/day, lovastatin 80 mg/day, or rosuvastatin 20 mg/day) would reduce the risk of IHD by nearly 70%. However, adverse effects are also dose related, and rosuvastatin is relatively untested. As moderate doses of statins substantially reduce the risk of IHD events it may be prudent to select commonly used doses of the older drugs for general use. This would also be cheaper, as simvastatin comes off patent in 2003 and lovastatin is already off patent. At doses of 40 mg/day these drugs lower LDL cholesterol by 1.8 mmol/l, which can reduce IHD events at age 60 years by 61% (51% to 71%). This is about double the currently recognised preventive effect of 30%.

Reasons for underestimation of effect on IHD
Why are the current estimates of effect so low? Firstly, five of the seven largest statin trials used pravastatin, which is relatively less effective (table 2). Secondly, risk falls relatively little within the first two years, and inclusion of these early events underestimates the preventive effect. Thirdly, a particular problem for the statin trials was the extent to which the intention to treat analysis underestimated the true preventive pharmacological effect because of non-adherence to the protocol (treated patients not taking their tablets and placebo patients taking statins). This last problem was partially overcome by relating the reduction in disease events to the average LDL cholesterol reduction in all randomised participants (treated and placebo). In this way non-adherence to the protocol was reflected in both a smaller than expected difference in LDL cholesterol concentration and a smaller than expected difference in the number of IHD events between the two groups. While this yields an accurate estimate of the risk reduction for the observed difference in LDL cholesterol it underestimates the effect of a given dose of the statin.

Effects of LDL cholesterol reduction on stroke
The estimated overall reduction in stroke of 10% (relative risk 0.90) for a 1.0 mmol/l reduction in LDL cholesterol is equivalent to a 17% (9% to 25%) reduction in stroke for a 1.8 mmol/l reduction LDL cholesterol, readily achievable with a statin (as 0.90^{1.8}=0.83). In people with existing vascular disease the reduction is 36% (0.78^{1.8}=0.64) The interpretation of the cohort study result showing a higher incidence of haemorrhagic stroke for a lower LDL cholesterol concentration is uncertain. Too few haemorrhagic strokes were identified in the randomised trials to resolve the
Conclusions

Statins can reduce IHD events by an estimated 61%. They reduce stroke by 17%, preventing non-fatal strokes with little effect on the risk of fatal stroke. Any possible excess of haemorrhagic stroke is greatly outweighed by the protective effect against IHD events and thromboembolic stroke.

We thank the following authors for unpublished data from trials: V Adhyyos (GREACE173), M Bortolini and P Serruys (LIPS173), A Tonkin and A Kirby (LIPIID183), T Pedersen and Tity for the conduct of the study, had access to the data, and interpreted the results. MRL is guarantor. We thank the following authors for unpublished data from trials: V Athyros (GREACE173), M Bortolini and P Serruys (LIPS173), A Tonkin and A Kirby (LIPIID183), T Pedersen and Tity for the conduct of the study, had access to the data, and interpreted the results. MRL is guarantor.

Contributors: MRL, NJW, and ARR wrote the paper. MRL and ARR abstracted the data. ARR carried out the statistical analyses. All authors interpreted the results. MRL is guarantor. Funding: ARR was supported by an NHS research and development programme award. The guarantor accepts full responsibility for the conduct of the study, had access to the data, and controlled the decision to publish.

Competing interests: NW and ML have filed a patent application on the formula of a combined pill to simultaneously reduce four cardiovascular risk factors.

14 Law Mr, Wald NJ, Morris JS, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; to go in same issue

(Accepted 8 April 2003)